- The Stifel 2016 Healthcare Conference on November 15, 2016, at 2:15 p.m. EST in New York, NY; and
- Jefferies 2016 London Healthcare Conference on November 16, 2016, at 3:20 p.m. GMT in London.
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Concert must submit toxicology data to the FDA before proceeding with Phase 2 trials.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.